Clinical Trial Update: CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial update of CDC-501 therapy in relapsed or refractory multiple myeloma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CDC-501

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED